<DOC>
	<DOCNO>NCT02727881</DOCNO>
	<brief_summary>A Phase 3 Study Efficacy Safety Squalamine Lactate Ophthalmic Solution 0.2 % Twice Daily Subjects Neovascular Age-Related Macular Degeneration . Patients receive injection ranibizumab . In addition , patient receive either Squalamine lactate 0.2 % eye drop Placebo eye drop . The study duration 2 year</brief_summary>
	<brief_title>Efficacy Safety Study Squalamine Ophthalmic Solution Subjects With Neovascular AMD</brief_title>
	<detailed_description>Phase 3 Study Efficacy Safety Squalamine Lactate Ophthalmic Solution 0.2 % Twice Daily Subjects Neovascular Age-Related Macular Degeneration Methodology : Phase III , multicenter , randomize , double-masked , placebo-controlled study conduct 2 period ( Year 1 Year 2 ) . Year 1 ( Screening/Baseline Week 52 ) : Patients randomly assign one 2 treatment group 1:1 ratio : - Squalamine lactate ophthalmic solution , 0.2 % BID ( Years 1 2 ) + ranibizumab every 4 week ( Year 1 ) PRN ranibizumab ( need , Year 2 ) - Placebo ophthalmic solution BID ( Years 1 2 ) + monthly ranibizumab every 4 week ( Year 1 ) PRN ranibizumab ( Year 2 ) , base optical coherence tomography ( OCT ) -guided re-treatment criterion</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Squalamine</mesh_term>
	<criteria>Age ≥ 50 year A diagnosis choroid neovascularization ( CNV ) secondary AMD CNV comprise least 50 % total lesion area fluorescein angiography ( FA ) Central subfield thickness ( spectral domain ( SD ) OCT central 1 mm ) ≥ 300 μm Bestcorrected visual acuity ( BCVA ) 20/40 20/320 ( 73 24letter score Early Treatment Diabetic Retinopathy Study [ ETDRS ] chart ) Neovascularization secondary condition AMD study eye ; Blood occupy great 50 % AMD lesion , blood &gt; 1.0 sq . mm underlie fovea Pigment epithelial detachment ( PED ) without associate subretinal fluid and/or cystic retinal change Clinical evidence diabetic retinopathy diabetic macular edema study eye Confounding ocular condition study eye affect interpretation OCT , VA assessment macular appearance ( e.g. , cataract , epiretinal membrane , retinal vascular occlusive disease ) Fibrosis atrophy , retinal epithelial tear center fovea study eye condition prevent VA improvement Uncontrolled glaucoma study eye , currently receive topical glaucoma medication study eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>AMD , CNV , choroidal neovascularization , retinal eye disease</keyword>
</DOC>